相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Differential Signature of Circulating miRNAs and Cytokines Between COVID-19 and Community-Acquired Pneumonia Uncovers Novel Physiopathological Mechanisms of COVID-19
Pedro Martinez-Fleta et al.
FRONTIERS IN IMMUNOLOGY (2022)
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
Henrry Diaz Londres et al.
IMMUNOTHERAPY (2022)
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
Rajashri R. Naik et al.
FRONTIERS IN PHARMACOLOGY (2022)
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Shruti Gupta et al.
JAMA INTERNAL MEDICINE (2021)
Healing after COVID-19: are survivors at risk for pulmonary fibrosis?
Lindsay T. McDonald
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2021)
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV
Nima Hemmat et al.
ARCHIVES OF VIROLOGY (2021)
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update
Waleed Alhazzani et al.
CRITICAL CARE MEDICINE (2021)
COVID-19: immunopathology, pathophysiological mechanisms, and treatment options
Larissa E. van Eijk et al.
JOURNAL OF PATHOLOGY (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches
Nagib Ahsan et al.
PROTEOMICS (2021)
Modeling and Molecular Dynamic Simulation of F(ab′)2 Fragment of Nimotuzumab for Lung Cancer Diagnostics
Yurika Sastyarina et al.
BIOINFORMATICS AND BIOLOGY INSIGHTS (2021)
IL-6 in inflammation, autoimmunity and cancer
Toshio Hirano
INTERNATIONAL IMMUNOLOGY (2021)
Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions
Jasmanda Wu et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Sangeun Jeon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
Tania Crombet Ramos et al.
FRONTIERS IN ONCOLOGY (2020)
An aberrant STAT pathway is central to COVID-19
Toshifumi Matsuyama et al.
CELL DEATH AND DIFFERENTIATION (2020)
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series
Andreas Stallmach et al.
CRITICAL CARE (2020)
EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor
Ahmed Elkamhawy et al.
BIOORGANIC CHEMISTRY (2019)
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC
Chong Hyun Suh et al.
LUNG CANCER (2018)
Propensity Score Methods for Bias Reduction in Observational Studies of Treatment Effect
Sindhu R. Johnson et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Chenfei Zhou et al.
CURRENT CANCER DRUG TARGETS (2017)
Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection
Thiagarajan Venkataraman et al.
JOURNAL OF VIROLOGY (2017)
The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis
Thiagarajan Venkataraman et al.
ANTIVIRAL RESEARCH (2017)
Nimotuzumab in combination with radiotherapy in high grade glioma patients A single institution experience
Maria Teresa Solomon et al.
CANCER BIOLOGY & THERAPY (2014)
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
Maria Teresa Solomon et al.
BMC CANCER (2013)
Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience
Ricardo Cabanas et al.
MABS (2013)
Treatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
Mayra Ramos-Suzarte et al.
CANCER BIOLOGY & THERAPY (2012)
Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors (Review)
Seiichiro Sakao et al.
ONCOLOGY LETTERS (2012)
Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile
Greta Garrido et al.
CANCER BIOLOGY & THERAPY (2011)
The complexity of targeting EGFR signalling in cancer: From expression to turnover
Sinto Sebastian et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
T Crombet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer
T Crombet et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Antiproliferative, antiangiogenic and proapoptotic activity of h-R3:: A humanized anti-EGFR antibody
T Crombet-Ramos et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
